# US 2022/0031818 A1 · Arginase1 polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031818 A1
- Document ID: US20220031818A1
- Status: Published application
- Kind: A1
- Application number: 17/278,838
- Filed: 2019-09-24
- Published: 2022-02-03
- Earliest claimed: 2018-09-24
- Assignees: IO Biotech ApS
- Applicants: Io Biotech Aps
- Inventors: Mads Hald Andersen
- Web page: https://patentgrep.com/patent/US20220031818A1

## CPC

- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 39/001154: {Enzymes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4244: {Enzymes}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12Y 305/03001: Arginase (3.5.3.1)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to novel polypeptides, which are derived from Arginase 1. The invention also relates to polynucleotides encoding the polypeptides. The invention also relates to compositions comprising the polypeptides and polynucleotides. The invention also concerns uses of the polypeptides, polynucleotides, and compositions.

## Claims

### Claim 1

A polypeptide consisting of any one of the following amino acid sequences:
(SEQ ID NO: 1)
a. ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL;
(SEQ ID NO: 2)
b. ISAKDIVYIGLRDVDPGEHYIIKTLGIKYFSMTEVDKL;
(SEQ ID NO: 3)
c. ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSM;
(SEQ ID NO: 4)
d. ISAKDIVYIGLRDVDPGEHYIIKTLGIKYFSM;
(SEQ ID NO: 5)
e. ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRLGIGK;
(SEQ ID NO: 6)
f. ISAKDIVYIGLRDVDPGEHYIIKTLGIKYFSMTEVDKLGIGK;
g. a sequence according to any one of a.-f. in which up to three amino acids are replaced by conservative substitution, provided that the said polypeptide does not exhibit significantly reduced immunogenicity to Arginase1 as compared to the polypeptide consisting of the corresponding sequence in which no substitution is made; or
h. a polynucleotide encoding the polypeptide of any one of a.-g., optionally comprised within a vector.

### Claim 2 (depends on 1)

The polypeptide of claim 1, which consists of the amino acid sequence of SEQ ID NO: 1.

### Claim 3 (depends on 1, 2)

The polypeptide of claim 1 or 2, in which the C terminal amino acid is replaced with the corresponding amide.

### Claim 4 (depends on 1, 2, 3)

A composition comprising the polypeptide or polynucleotide of any one of claims 1 to 3 and an adjuvant.

### Claim 5 (depends on 4)

A composition according to claim 4, comprising at least one pharmaceutically acceptable diluent, carrier or preservative.

### Claim 6 (depends on 4, 5)

A composition according to claim 4 or 5 wherein the adjuvant is selected from the group consisting of bacterial DNA based adjuvants, oil/surfactant based adjuvants, viral dsRNA based adjuvants, imidazochinilines, and a Montanide ISA adjuvant.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A method of treating or preventing a disease or condition in a subject, the method comprising administering to the subject the polypeptide or polynucleotide of any one of claims 1 to 3 or the composition of claims 4 to 6.

### Claim 8 (depends on 7)

The method of claim 7 wherein the disease or condition is characterized at least in part by inappropriate or excessive immune suppressive function of an Arginase, and/or said wherein disease or condition is cancer.

### Claim 9 (depends on 7, 8)

The method of claim 7 or 8 wherein the disease or condition is cancer and optionally wherein the method further comprises the simultaneous or sequential administration of an additional cancer therapy, preferably an antibody.

### Claim 10 (depends on 7, 8, 9)

The method of any one of claims 7 to 9 wherein said cancer is breast, lung, colon or prostate cancer, or is a melanoma, or is a leukemia, preferably acute myeloid leukemia (AML).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6)

A method of stimulating arginase1-specific T cells, the method comprising contacting the cells with the polypeptide of any one of claims 1 to 3 or the composition of claims 4 to 6.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cells are present in a sample taken from a healthy subject or from a cancer patient, optionally a tumour sample.
